glp 1 als The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of Current Insights, Advantages and Challenges

Romariz and colleagues show that GLP-1 agonists decrease body weight, body mass index (BMI), and waist circumference in children aged 619 with obesity

Injectable use: Not FDA-approved

Health systems and clinicians should evaluate how these changes affect patient demand, prescribing patterns, and care coordination, while remaining alert to further guidance from CMS and the FDA as demonstration models unfold.

A Frank Discussion About Cancer Risk I cannot in good conscience discuss these peptides without directly addressing cancer concerns

Calcium signaling and episodic secretion of gonadotropin-releasing hormone in hypothalamic neurons